
|Articles|April 16, 2007
Valve risk leads to withdrawal of pergolide (Permax, Valiant)
Two high-quality reports in the New England Journal of Medicine confirming the risk of valvulopathy with the use of pergolide (Permax, Valiant) have led the FDA to remove the drug from the U.S. market. Two generic forms of the drug, made by Teva and Par Pharmaceuticals, will also be withdrawn.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Approves Afibercept-Boav as Biosimilar to Afibercept for Diabetic Macular Edema
2
FDA Approves Risperidone Injection for Bipolar I Disorder in Adults
3
Vaccine Messaging for Teens Should Tailor to Personal Perspectives
4
CVS Pharmacy Acquires Select Rite Aid Assets in 3 States, Accounting for Over 600 Stores
5